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Angiotensin II (AngII) causes hypertension (HTN) and promotes renal injury while simultaneously inducing reno-protective
enzymes like heme oxygenase-1 (HO-1). We examined the modulatory role of HO on sub-pressor angiotensin II (SP-AngII)
induced renal inﬂammation and injury. We ﬁrst tested whether the SP-AngII-induced renal dysfunction, inﬂammation and injury
are exacerbated by either preventing (chronic HO-1 inhibition) or reversing (late HO-1 inhibition) SP-AngII-induced HO (using
tinprotoporphyrin;SnPP).WenextexaminedwhetheradditionalchronicorlateinductionofSP-AngII-inducedHO(usingcobalt
protoporphyrin;CoPP),preventsoramelioratesrenaldamage.WefoundthatneitherchronicnorlateSnPPalteredbloodpressure.
ChronicSnPPworsenedSP-AngII-inducedrenaldysfunction,inﬂammation,injuryandﬁbrosis,whereaslateSnPPworsenedrenal
dysfunction but not inﬂammation. Chronic CoPP prevented HTN, renal dysfunction, inﬂammation and ﬁbrosis, but surprisingly,
not the NGAL levels (renal injury marker). Late CoPP did not signiﬁcantly alter SP-AngII-induced HTN, renal inﬂammation or
injury, but improved renal function. Thus, we conclude (a) endogenous HO may be an essential determining factor in SP-AngII
induced renal inﬂammation, injury and ﬁbrosis, (b) part of HO’s renoprotection may be independent of blood pressure changes;
and (c) further induction of HO-1 protects against renal injury, suggesting a possible therapeutic target.
1.Introduction
Angiotensin II (AngII) is one of the major factors playing a
role in the development of chronic kidney disease. It does so
by virtue of its hemodynamic, prooxidant, proinﬂammatory,
and proﬁbrotic eﬀects. However, along with its detrimental
eﬀects, AngII has been found to induce adaptive, protective
pathways. One such cytoprotective system is via heme oxy-
genase (HO). HO is the rate-limiting step in the metabolism
of heme, breaking it down into biliverdin with the resultant
r e l e a s eo ff e r r i ci r o na n dc a r b o nm o n o x i d e[ 1–3]. It exists as
two isoforms, HO-1 and HO-2. HO-1 is an inducible form
that is upregulated by various stimuli including lipopolysac-
charide, nitric oxide, and AngII [1, 2], whereas HO-2 is con-
stitutively expressed [3]. The cytoprotective properties of
HOareattributedtotheantioxidant,anti-inﬂammatory,and
vasorelaxant actions of the end products of heme metabo-
lism; biliverdin with the resultant bilirubin and carbon mo-
noxide [4]. Previous studies have demonstrated the impor-
tance of HO in dampening the hypertensive and renal vaso-
constrictoreﬀectsofAngII[5–7].However,thesestudiesem-
ployed pressor doses of AngII. Such high doses of AngII may
not accurately reﬂect the balance between the injurious and
adaptive factors that are triggered by physiological doses of
AngII. A model that is more analogous to clinical situations
is one in which AngII levels are elevated, but within a patho-
physiologic range. This is achieved by chronically infus-
ingsubpressordosesofAngII(SP-AngII).Thismodelischar-
acterized by the development of salt-sensitive hypertension
(HTN), increased expression of proinﬂammatory factors,
oxidative stress, and progressive renal injury [4, 5, 8–10].
We recently examined the renal vascular eﬀects of acute2 International Journal of Hypertension
inhibition of HO after 2 weeks of SP-AngII [11]; however,
the modulatory eﬀects of HO on SP-AngII-induced renal
inﬂammation and injury are incompletely understood. In
the present study, we evaluated the role of SP-AngII-induced
HO-1 in modulating the injurious eﬀects of SP-AngII.
We tested whether chronically inhibiting HO exacerbates
SP-AngII-induced renal inﬂammation and injury and also
whether inhibiting HO late in the course of SP-AngII
alters the renal dysfunction. In addition, because inducing
overexpression of HO-1 may represent a potential therapeu-
tic target for preventing AngII-induced damage, we tested
whether chronically inducing HO-1 prevented renal injury
and whether inducing HO-1 late in the course of SP-AngII-
induced HTN ameliorates renal inﬂammation and damage.
2. Methods
All experiments were approved by the Institutional Animal
Care and Use Committee of the University of Mississippi
Medical Center and were performed in accordance with the
Guide for the Care and Use of Laboratory Animals of the
National Institutes of Health.
2.1. Experimental Groups and Design. Male Sprague Dawley
rats (Harlan Teklad, Indianapolis, IN USA) (263 ± 20g)
maintained on standard rat chow with water ad libitum were
usedinallexperiments.Allanimalswereinsertedwithosmo-
tic minipumps (2ML2, Alzet minipumps, DURECT Corp.,
Cupertino, CA, USA), which infused either a vehicle (saline)
or AngII (200ng/kg/min) subcutaneously for 14 days as pre-
viously described [6, 12, 13] .W eu s e dt h i sd o s eo fS P - A n g I I
because it increases plasma AngII to levels that do not cause
immediate vasoconstriction, yet reliably cause HTN and lead
to renal inﬂammation and injury within the time frame of
the experiments. We then tested the involvement and eﬀects
ofHOintheseanimals.ForthiswemodulatedHOactivityin
two ways: the ﬁrst by preemptively modulating the activity of
HO (treating throughout the SP-AngII infusion) and second
by reversing or enhancing its activity after SP-AngII has been
present for 12 days. Initially, we tested whether chronically
inhibiting HO (tin protoporphyrin (SnPP) 30μmol/kg, i.p.,
every 3 days) worsens renal inﬂammation and injury. We
then tested whether blocking the eﬀect of HO near the end
of the 2 -week infusion (late SnPP; 50μm o l / k g ,i . p .o nd a y
12), worsens the renal parameters. Because further induc-
tion of HO-1 may protect against AngII-induced HTN, we
tested whether chronic induction of HO-1 (cobalt protopor-
phyrin(CoPP)30μmol/kg,i.p.,every3days)bluntsrenalin-
ﬂammation and injury. Finally, we tested whether inducing
HO-1 near the end of the SP-AngII infusion (late CoPP;
50μmol/kg, i.p, on day 12) can ameliorate the adverse aﬀects
of SP-AngII.
Systolic blood pressure (SBP) was measured during the
14-day course of SP-AngII/vehicle infusion by tail cuﬀ pleth-
ysmography (TCP) (Harvard Apparatus, Holliston MA,
USA) in conscious, trained animals. On day 14 of the proto-
col, blood was collected and the animals were housed in me-
tabolic cages, and urine was collected for 24 hours. The
animalswerethensacriﬁced,andthekidneyswereharvested.
All organs were weighed and ﬂash-frozen using liquid nitro-
gen.
2.2. Measurements
2.2.1. Renal Function, Oxidative Stress, Inﬂammation, and In-
jury. Renal function was assessed by measuring plasma cre-
atinine using a Quantichrom Creatinine Assay kit (BioAssay
Systems). The kidney cortices were homogenized using a tis-
sue homogenizer (IKA Works) in radioimmunoprecipitation
assay (RIPA) buﬀer (10μL of phenylmethylsulfonyl ﬂuoride
(PMSF) +10μL sodium orthovanadate +10–20μLp r o t e a s e
inhibitor cocktail per mL of 1X RIPA lysis buﬀer). A bicin-
choninicacid(BCA;Pierce,Rockford,IL,USA)proteinassay
kitwasusedforthecalorimetricdetectionandquantiﬁcation
ofthetotalproteininthekidneyhomogenates.Renalinﬂam-
mation was estimated by analyzing the renal interleukin-6
levels (IL-6). Kidney cortex homogenates from all groups
wereanalyzed simultaneously forIL-6 levels(Quantikine Rat
IL-6 Immunoassay kit) (R&D Systems, Minneapolis MN,
USA). Finally renal injury was determined by measuring the
following: urinary levels of neutrophil gelatinase-associated
lipocalin levels (NGAL, by ELISA; Assay Designs, Ann
Arbor, MI, USA); renal tissue levels of kidney injury marker
(KIM-1, by ELISA; R&D Systems, Minneapolis, MN, USA);
apoptosis, as measured by cytochrome-C levels (by ELISA;
R&D Systems, Minneapolis, MN, USA), and the proﬁbrotic
signal, transforming growth factor- beta 1 (TGF-β1; by
ELISA; R&D Systems, Minneapolis, MN, USA).
2.3. HO Activity. HO activity was determined by measuring
the amount of bilirubin produced using a well established
protocol [14]. Brieﬂy, the kidney cortices were processed
using a homogenization buﬀer (sucrose, monobasic and
dibasic potassium phosphate, EDTA and PMSF at ph 7.7)
The protein content of this homogenate was measured and
then mixed with a potassium phosphate buﬀer (monobasic
and dibasic potassium phosphate with water at ph 7.4), Glu-
cose-6-phosphate, glucose-6-phosphate dehydrogenase, be-
ta-nicotinamide diamine phosphate (β-NADP) and hemin
to get a 1.2mL reaction. The reaction was then incubated for
1hrat37 ◦C in a dark room, after which 1.2mL of chloro-
form was added and the mixture vortexed for 15 seconds.
The reaction was then frozen overnight, thawed and vor-
texed. The samples were centrifuged at 15,000g for 10 min-
utes, resulting in a ring-like layer separating the supernatant
from the lower half. The supernatant was discarded and the
absorbance was measured at 464 and 530nm in a spectro-
photometer, using an extinction coeﬃcient of 40mM/cm for
bilirubin. The resulting HO activity was expressed as nmoles
of bilirubin/mg of kidney protein/hr (nmol bil/mg pro-
tein/hour).
2.4. Statistics. All variables were expressed as mean ± SEM.
An unpaired Student’s t-test was used to perform compari-
sons between two groups. The ANOVA test was employed
to statistically compare two or more groups. StatisticalInternational Journal of Hypertension 3
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Figure 1: HO activity after chronic and late HO modulation. HO
activity is determined by measuring the bilirubin formation in the
following groups. Vehicle- (Veh-) treated (n = 6), SP-AngII-treated
(n = 6), chronic-SnPP- (Ch-SnPP-) treated (n = 6), SP-AngII/Ch-
SnPP-treated (n = 6), late-SnPP-treated (n = 5), SP-AngII/late-
SnPP-treated (n = 5), chronic-CoPP- (Ch-CoPP-) treated (n = 6),
SP-AngII/Ch-CoPP-treated (n = 6), late-CoPP-treated (n = 5), SP-
AngII/late-CoPP-treated (n = 6) rats.
∗P<0.05 versus. control,
#P<0.05 versus. SP-AngII.
signiﬁcance was established at a P value less than 0.05. We
utilized the Instat software (GraphPad, v3.06; La Jolla, CA,
USA) to analyze all data.
3. Results
3.1. HO Activity (Figure 1). We ﬁrst examined whether our
therapeutic protocols were eﬀective in inhibiting or inducing
HO activity. SP-AngII increased HO activity from 0.9 ± 0.01
to 2.1 ± 0.04nmoles of bilirubin/mg protein/hour. Neither
chronic nor late administration of SnPP decreased HO
activity in control animals (0.63±0.33 and 0.8±0.01nmoles
of bilirubin/mg protein/hour, resp.) but both lowered HO
activity in SP-AngII treated rats (from 2.1±0.04 to 0.7±0.02
and 0.7 ± 0.12nmoles of bilirubin/mg protein/hour, resp.).
Chronic and late induction of HO-1 with CoPP increased
HO activity in control animals (from 0.9 ± 0.01 to 2.1 ± 0.3
and 1.3 ± 0.2nmoles of bilirubin/mg protein/hour, resp.)
and further elevated SP-AngII-induced HO activity (from
2.1 ± 0.04 to 3 ± 0.25 and 3 ± 0.21nmoles of bilirubin/mg
protein/hour, resp.).
3.2. Blood Pressure (Figure 2). Chronic infusion of Sp-Ang
II increased the blood pressure from 122 ± 1mm Hg to
167±2mm of Hg. Neither chronic nor late inhibition of HO
augmented SP-AngII- induced HTN (167 ± 2 versus 174 ±
2 and 167 ± 2 versus 173 ± 1, resp.). On the other hand,
chronic induction of HO-1 prevented the SP-AngII-induced
elevationinSBP(SBPwas123±4mmHgafter2weeksofSP-
AngII). Late induction did not signiﬁcantly blunt SP-AngII-
induced HTN (154 ± 10mmHg). Neither inhibition nor
induction of HO altered blood pressure in vehicle-treated
animals.
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Figure 2: Eﬀect of SP-Ang II and HO modulation on the SBP in the
following groups Vehicle- (Veh-) treated (n = 6), SP-AngII-treated
(n = 6), chronic-SnPP- (Ch-SnPP-) treated (n = 6), SP-AngII/Ch-
SnPP-treated (n = 6), late-SnPP-treated (n = 5), SP-AngII/late-
SnPP-treated (n = 5), chronic-CoPP- (Ch-CoPP-) treated (n = 6),
SP-AngII/Ch-CoPP–treated (n = 6), Late CoPP-treated (n = 5),
SP-AngII/late-CoPP-treated (n = 6) rats.
∗P<0.05 versus. control,
#P<0.05 versus. SP-AngII.
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Figure 3: Eﬀect of SP-Ang II and HO modulation on the plasma
creatinine levels was determined in the following groups; Vehicle
(Veh) treated (n = 6), SP-AngII-treated (n = 6), chronic-SnPP-
(Ch-SnPP-) treated (n = 6), SP-AngII/Ch-SnPP-treated (n = 6),
late SnPP-treated (n = 5), SP-AngII/late-SnPP-treated (n = 5),
chronic-CoPP- (Ch-CoPP-) treated (n = 6), SP-AngII/Ch-CoPP–
treated (n = 6), and late-CoPP-treated (n = 5), SP-AngII/late
CoPP-treated (n = 6) rats.
∗P<0.05 versus. control,
#P<0.05
versus. SP-AngII.
3.3. Renal Function, Inﬂammation and Injury. SP-AngII in-
creased plasma creatinine from 0.5 ± 0.02mg/dL to 0.9 ±
0.03mg/dL, suggesting that this dose of SP-AngII impairs
renal function (Figure 3). Chronic inhibition of HO exac-
erbated SP-AngII-induced increases in plasma creatinine
(1.2 ± 0.06mg/dL). Late HO inhibition, despite having only
ac o u p l eo fd a y st oe x e r ti t se ﬀect, also elevated SP-AngII-
induced increases in plasma creatinine (1.1 ± 0.06mg/dL).4 International Journal of Hypertension
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Figure 4: Eﬀect of SP-Ang II and HO modulation on the
inﬂammatorycytokine-IL-6wasestimatedinthefollowinggroups;
Vehicle (Veh) treated (n = 6), SP-AngII-treated (n = 6), chronic-
SnPP- (Ch-SnPP-) treated (n = 6), SP-AngII/Ch-SnPP-treated (n =
6), late-SnPP-treated (n = 5), SP-AngII/late-SnPP-treated (n = 5),
chronic-CoPP- (Ch-CoPP-) treated (n = 6), SP-AngII/Ch-CoPP–
treated (n = 6), late-CoPP-treated (n = 5), SP-AngII/late CoPP-
treated (n = 6) rats.
∗P<0.05 versus. control,
#P<0.05 versus.
SP-AngII.
As with blood pressure, chronic induction of HO-1 prevent-
ed the rise in plasma creatinine caused by SP-AngII (0.6 ±
0.03mg/dL), whereas late induction of HO-1 blunted this
increase(0.8±0.04mg/dL).Neitherinhibitionnorinduction
of HO altered plasma creatinine in vehicle-treated animals.
Renal inﬂammation was assessed by measuring IL-6
levels (Figure 4). SP-AngII increased IL-6 levels from 8.5 ±
1.7pg/μg/mL to 20.9 ± 4.3pg/μg/mL. Chronic HO inhibi-
tion accentuated SP-AngII-induced IL-6 levels (to 33.9 ±
3.1pg/μg/mL). In contrast to plasma creatinine, late HO
inhibition did not exacerbate the SP-AngII-induced IL-6
(24.4 ± 0.8pg/μg/mL). Chronic induction of HO-1 did not
completely block SP-AngII-induced increases in IL-6 but
signiﬁcantly blunted it (15.6 ± 1.1pg/μg/mL), whereas late
induction did not signiﬁcantly alter IL-6 levels (23.1 ±
2.5pg/μg/mL).NeitherinhibitionnorinductionofHOalter-
ed IL-6 in vehicle-treated animals.
Renal damage was assessed by measuring the levels of
therenalinjurymarkerNGAL(Figure 5).SP-AngIIincreased
NGALfrom0.3±0.01 to4±0.49UI/mgcreatinine,thussug-
gesting that this dose of Ang II was inducing renal damage.
Chronic HO inhibition markedly exacerbated SP-AngII-
induced NGAL (to 15.9 ± 1.35UI/mg creatinine). Late HO
inhibition, despite having only a short duration to act, also
increased SP-AngII-induced NGAL (to 13.7 ± 1.21UI/mg
creatinine). However, neither chronic nor late induction
of HO-1 blunted the SP-AngII-induced NGAL elevation
(5.1 ± 0.56 and 5 ± 0.82UI/mg creatinine, resp.), which is
in marked contrast to their eﬀects on blood pressure, renal
function and inﬂammation. This raises the possibility that
SP-AngII-induced NGAL might not be always in tandem
with co-existing renal injury. Hence we assessed additional
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Figure 5: Eﬀect of SP-Ang II and HO modulation on Urinary
NGAL excretion was measured in the following groups; Vehicle-
(Veh-) treated (n = 6), SP-AngII-treated (n = 6), chronic-SnPP-
(Ch-SnPP-) treated (n = 6), SP-AngII/Ch-SnPP-treated (n = 6),
late-SnPP-treated (n = 5), SP-AngII/late SnPP-treated (n = 5),
chronic-CoPP- (Ch-CoPP-) treated (n = 6), SP-AngII/Ch-CoPP–
treated (n = 6), late-CoPP-treated (n = 5), SP-AngII/Late-CoPP-
treated (n = 6) rats.
∗P<0.05 versus. control,
#P<0.05 versus.
SP-AngII.
markers of renal injury such as KIM-1 (biomarker of injury),
cytochrome C (apoptosis) and TGF-β1(ﬁbrosis). Since we
were mainly interested in determining whether inducing
HO-1 blunts frank injury, we only measured these parame-
ters in the animals with chronic HO inhibition and induc-
tion. As shown in Figure 6(a), SP-AngII increased KIM-1
(from 54.5 ± 3.7t o4 6 8 .9 ± 120.6pg/μg kidney protein) was
increased by chronic HO inhibition (853.3 ± 145.1pg/μg
kidney protein), and blunted by chronic induction (140.8 ±
92.55pg/μg kidney protein). This same pattern was seen
with both cytochrome c and TGF-β1, except that SP-AngII
induced increases in these parameters was completely block-
ed by chronic CoPP, (Figures 6(b) and 6(c),r e s p . ) .
4. Discussion
HO-1 is an important cytoprotectant which is induced in the
kidney by oxidative stress, injury and certain hormones in-
cluding AngII, and thus its role in modulating renal injury
has been increasingly studied. Our laboratory has a long-
standing interest in the interactions between AngII and HO
in determining renal function and injury. In our recent
study, we examined the eﬀect of acutely inhibiting HO on
renal hemodynamics in rats that were treated with very low
doses of SP-AngII (50ng/kg/min IV) [11]. We found that
although renal HO-1 was not increased by this dose of SP-
AngII, blocking it still modulated renal hemodynamics in
SP-AngII-treated but not control rats. The present study is
an extension of our previous one in that we now evaluated
the impact of modulating HO activity on SP-AngII-induced
renal inﬂammation and injury. We modulated HO activity
by preemptively/chronically modulating the activity of HO,International Journal of Hypertension 5
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Figure 6: Eﬀect of SP-Ang II and HO modulation on renal (a) KIM-1, (b) cytochrome c, and (c) TGF-β1 expression was estimated in the
following groups; Vehicle (Veh) treated (n = 6), SP-AngII-treated (n = 6), Chronic SnPP (Ch-SnPP)-treated (n = 6), SP-AngII/Ch-SnPP-
treated(n = 6),ChronicCoPP(Ch-CoPP)-treated(n = 6), SP-AngII/Ch-CoPP-treated (n = 6),
∗p<0.05versus.Control, #p<0.05versus.
SP-AngII.
and by reversing or enhancing its activity late in the course of
SP-AngII-induced HTN. We found that chronic and late HO
inhibition exacerbated SP-AngII-induced renal dysfunction
without signiﬁcantly increasing the blood pressure. We also
found that chronic induction prevented SP-AngII-induced
HTN as well as the majority of the parameters of renal
inﬂammation and injury, whereas late-induction did not
signiﬁcantly reduce blood pressure, renal inﬂammation or
NGAL, but improved plasma creatinine.
AngII is an important contributor to the pathogenesis of
various forms of HTN and is also a major determinant in the
progression of chronic kidney disease by virtue of its hemo-
dynamic, proinﬂammatory, and proﬁbrotic eﬀects [15–
17]. Indeed, numerous studies have demonstrated that the
chronic infusion of AngII causes HTN, decreases GFR, while
simultaneously inducing inﬂammatory signaling leading to
renal injury, apoptosis and ﬁbrosis [1, 2, 18]. However, most
of these studies used very high pressor doses of AngII which6 International Journal of Hypertension
induce rapid and aggressive renal damage, regardless of the
presenceofanycytoprotection,andhencemaynotreﬂectthe
sequence of inﬂammation and injury in human disease. Our
interests lie in studying the balance between the injurious
and cytoprotective factors that are induced by more clinically
relevant levels of AngII. In previous studies, we used doses of
SP-AngII that increase oxidative stress and proinﬂammatory
signaling, but do not consistently cause sustained HTN nor
cause frank renal injury. In the present study our aim was to
evaluate the modulatory eﬀect of HO on SP-AngII-induced
renal inﬂammation and injury. Thus we modiﬁed our SP-
AngII model slightly to one that consistently increases blood
pressure (it increased within 4 days) and leads to renal injury
within the 2-week timeframe of our experiments, and HO-
1 induction. Therefore, this model of SP-AngII is a valuable
tooltoexaminethemodulatoryeﬀectsofHOonrenalinjury.
Various previous studies have found discrepant eﬀects of
HO inhibition on HTN [11, 14, 19]. Several studies have
found that blocking HO results in an increase in blood
pressure, whereas others show no change or even a decrease
[11, 19]. Indeed, we previously found that HO blockade
decreased mean arterial pressure (MAP) in anesthetized SP-
AngII rats [11], which appeared to be due to a fall in cardiac
output. The diﬀerences in blood pressure responses in the
v a r i o u ss t u d i e sm a yb ed u et od i ﬀerences in the species and
protocols of AngII used. In the present study, we found
that SnPP did not alter SBP in conscious SP-AngII rats,
whichatﬁrstglanceappearstocontradictourpreviousstudy.
However, this variation may be due to the diﬀerent SP-
AngII models used, or to how blood pressure was measured.
Indeed, the SnPP rats in the current study also tended to
havealowerMAPwhenmeasuredunderanesthesia(datanot
shown).
Despite not altering the blood pressure, SnPP aggravated
all the renal injury parameters suggesting that SP-AngII-
induced HO is markedly attenuating the deleterious actions
of AngII on the kidney. Interestingly, even late inhibition
of HO activity caused a deleterious eﬀect on renal function
and NGAL levels. While, the mechanism by which late HO
inhibition worsened renal function is likely due to the hemo-
dynamic eﬀects of HO inhibition [11], the mechanisms for
the increased NGAL levels are unclear. Because NGAL does
not represent cumulative injury, but rather ongoing and pro-
gressiverenalinjury[20],itsincreasemaydenoteanaccentu-
ation in the rate of renal injury following late administration
of SnPP that may be due to HO-inhibition or a direct renal
toxic eﬀect of SnPP. We speculate that the increase in NGAL
was not emulated by changes in IL-6 because the relatively
brief duration of HO inhibition was insuﬃcient to detect
worsening of renal inﬂammation. Altogether, our ﬁndings
suggest that SP-AngII-induced HO tempers renal injury in
a manner that is not reliant on lowering blood pressure.
Because HO-1 has profound renoprotective eﬀects in a
variety of renal diseases, there has been much interest in
examining the therapeutic potential of inducing the HO-
1 system in an attempt to ameliorate progression of renal
injury. We therefore examined whether further induction of
HO-1 during SP-AngII can further protect against SP-AngII-
induced renal injury. We found that chronically inducing
HO-1 completely blocked SP-AngII-induced HTN and real
dysfunction. It also blunted the increase in renal inﬂam-
mation, but surprisingly not the NGAL levels. These results
were puzzling to us and therefore we further evaluated renal
injury with other parameters; KIM-1, cytochrome c, and
TGF-β1. We found that chronic HO-1 induction completely
blocked SP-AngII-induced increases in all 3 parameters
suggesting prevention of renal injury despite the high NGAL
level. Although the reason for this discrepancy is unclear,
it insinuates that under certain conditions NGAL may be
induced independent of injury. However, we cannot discard
the possibility that NGAL may simply be the earliest of the
markers we measured to increase with injury.
Incontrasttochronicinduction,lateHO-1inductiondid
not normalize blood pressure, nor did it alter IL-6 or NGAL.
This was not unexpected as it seems unlikely that the brief
durationofadditionalHO-1inductionwouldbesuﬃcientto
reverse the 12 days of SP-AngII-induced renal inﬂammation
and injury. However, despite the lack of eﬀect on blood
pressure, late HO-1 induction signiﬁcantly improved renal
function, providing further evidence that under these condi-
tions HO modulates renal but not systemic hemodynamics.
Insummary,ourresultsshowthatSp-AngII-inducedHO
blunts the deleterious eﬀects of SP-AngII on renal hemo-
dynamics, inﬂammation and injury without signiﬁcantly
lowering blood pressure. Moreover, if induced early enough,
HO may prevent SP-AngII-induced HTN and renal injury.
Hence, we speculate that the activity of endogenous HO is
an important determinant in the progression of SP-AngII-
induced HTN and renal injury, and that at least part of its
renoprotective eﬀect is independent of its blood pressure
loweringproperties. Thus,conditions whichlowerHOactiv-
itymayrenderthekidneymoresusceptibletoinjury[12,13],
while also raising the possibility of targeting HO-1 induction
as a therapeutic measure to protect against renal injury.
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